Stock Track | Harrow Health Plunges 5.30% Pre-market Following Disappointing Q3 Results

Stock Track11-11

Harrow Health Inc (HROW) stock is experiencing a pre-market plunge of 5.30% on Tuesday, following the release of its third-quarter 2025 financial results. The specialty pharmaceutical company's earnings and revenue fell short of analysts' expectations, triggering a sell-off that began in after-hours trading on Monday.

The company reported adjusted earnings per share (EPS) of $0.33, which, while beating the FactSet analyst estimate of $0.29, fell significantly short of the $0.22 per share expected by Wall Street. Revenue for the quarter came in at $71.6 million, representing a 45% year-over-year increase but missing analyst expectations of $73.7 million. The underperformance was largely attributed to disappointing results from Triesence, a steroid used to treat various eye diseases.

Despite the setback, Harrow Health's CEO Mark Baum remains optimistic about Triesence's future, expecting it to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation segment. However, the market's immediate reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading continues, all eyes will be on how the stock performs throughout the regular session and whether the company can address investor concerns about its product performance and overall financial health.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167838100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167838100","market":"hk","top_or_hot":-1,"title":"Stock Track | Harrow Health Plunges 5.30% Pre-market Following Disappointing Q3 Results","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) stock is experiencing a pre-market plunge of 5.30% on Tuesday, following the release of its third-quarter 2025 financial results. The specialty pharmaceutical company's earnings and revenue fell short of analysts' expectations, triggering a sell-off that began in after-hours trading on Monday.</p>\n\n<p>The company reported adjusted earnings per share (EPS) of $0.33, which, while beating the FactSet analyst estimate of $0.29, fell significantly short of the $0.22 per share expected by Wall Street. Revenue for the quarter came in at $71.6 million, representing a 45% year-over-year increase but missing analyst expectations of $73.7 million. The underperformance was largely attributed to disappointing results from Triesence, a steroid used to treat various eye diseases.</p>\n\n<p>Despite the setback, Harrow Health's CEO Mark Baum remains optimistic about Triesence's future, expecting it to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation segment. However, the market's immediate reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading continues, all eyes will be on how the stock performs throughout the regular session and whether the company can address investor concerns about its product performance and overall financial health.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Plunges 5.30% Pre-market Following Disappointing Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Plunges 5.30% Pre-market Following Disappointing Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) stock is experiencing a pre-market plunge of 5.30% on Tuesday, following the release of its third-quarter 2025 financial results. The specialty pharmaceutical company's earnings and revenue fell short of analysts' expectations, triggering a sell-off that began in after-hours trading on Monday.</p>\n\n<p>The company reported adjusted earnings per share (EPS) of $0.33, which, while beating the FactSet analyst estimate of $0.29, fell significantly short of the $0.22 per share expected by Wall Street. Revenue for the quarter came in at $71.6 million, representing a 45% year-over-year increase but missing analyst expectations of $73.7 million. The underperformance was largely attributed to disappointing results from Triesence, a steroid used to treat various eye diseases.</p>\n\n<p>Despite the setback, Harrow Health's CEO Mark Baum remains optimistic about Triesence's future, expecting it to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation segment. However, the market's immediate reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading continues, all eyes will be on how the stock performs throughout the regular session and whether the company can address investor concerns about its product performance and overall financial health.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1167838100","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167838100","pubTimestamp":1762857980,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc (HROW) stock is experiencing a pre-market plunge of 5.30% on Tuesday, following the release of its third-quarter 2025 financial results. The specialty pharmaceutical company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"个股追踪|哈罗健康第三季度业绩令人失望盘前暴跌5.30%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) stock is experiencing a pre-market plunge of 5.30% on Tuesday, following the release of its third-quarter 2025 financial results. The specialty pharmaceutical company's earnings and revenue fell short of analysts' expectations, triggering a sell-off that began in after-hours trading on Monday.\nThe company reported adjusted earnings per share (EPS) of $0.33, which, while beating the FactSet analyst estimate of $0.29, fell significantly short of the $0.22 per share expected by Wall Street. Revenue for the quarter came in at $71.6 million, representing a 45% year-over-year increase but missing analyst expectations of $73.7 million. The underperformance was largely attributed to disappointing results from Triesence, a steroid used to treat various eye diseases.\nDespite the setback, Harrow Health's CEO Mark Baum remains optimistic about Triesence's future, expecting it to become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation segment. However, the market's immediate reaction suggests that investors may need more convincing before regaining confidence in Harrow Health's growth prospects. As trading continues, all eyes will be on how the stock performs throughout the regular session and whether the company can address investor concerns about its product performance and overall financial health.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167838100","isCrawlerRequest":true}